Targeted delivery of nanoparticles for in vivo CAR T therapy

Strike Pharma is a Swedish biotech company with a proprietary technology for targeted LNP delivery, enabling in vivo CAR-T therapies for autoimmune disease and cancer. Specifically our technology provides a solution for CMC challenges related to long-term storage, based on an affinity conjugation technology that allows post-storage attachment the targeting antibody to the LNP.

 

Learn more about our Technology, Pipeline and Disease indications, and see our Publications and posters.

Latest News

February 10, 2026

Strike Pharma receives Eurostars grant for a novel in vivo CAR-T project in collaboration with AbClon Inc.

Latest Events

September 24, 2023

Strike Pharma presents further developments at CICON23